Search Results - "Mueller, Eric C."
-
1
Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial
Published in The Lancet (British edition) (10-06-2017)“…Summary Background Patients who have had inadequate response to tumour necrosis factor inhibitors have fewer treatment options and are generally more treatment…”
Get full text
Journal Article -
2
Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial
Published in The Lancet (British edition) (04-01-2020)“…Ixekizumab, a high-affinity interleukin-17A (IL-17A) monoclonal antibody, has previously shown efficacy in radiographic axial spondyloarthritis (also known as…”
Get full text
Journal Article